Akin to the successes of BRAF inhibitors and similar targeted drugs, an expanding type of cancer therapeutics in the form of small molecules aims to couple with existing therapies to improve response rates in metastatic melanoma and other malignancies. The gene discussed is BRAF; the disease is metastatic melanoma.